Table 1 Summarized Metabolic, Glycemic, and Lipidemic Effects of THCV

 Human Studies

Increase FFA suppression index (FFA auc/Insulin auc) (Muniyappa et al. 2013)

Induces glucose intolerance in men (Muniyappa et al. 2013)

Impaired adipose tissue insulin sensitivity (Muniyappa et al. 2013)

Increase indices of adipose tissue insulin resistance (Muniyappa et al. 2013)

Normal glucose tolerance due to no impairments on β-cell glucose sensitivity, rate sensitivity, or insulin secretion (Muniyappa et al. 2013)

Decreased fasting plasma glucose (Jadoon et al. 2016)

Improved pancreatic β-cell function (Jadoon et al. 2016)

No difference in total cholesterol level (Muniyappa et al. 2013)

Lower plasma HDL level (Muniyappa et al. 2013) vs. plasma HDL unaffected (Jadoon et al. 2016)

No difference in LDL cholesterol (Muniyappa et al. 2013)

No difference in triglycerides (Muniyappa et al. 2013)

No difference FFA levels (Muniyappa et al. 2013)

Improved fasting plasma glucose (Wargent et al. 2013)

Pancreatic CB1R activation leads to β-cell death and impairs insulin secretion (Muniyappa et al. 2013)

Improved glucose tolerance (Wargent et al. 2013)

Increased insulin sensitivity (Wargent et al. 2013)

Restores insulin sensitivity in cells that are insulin-resistant (Wargent et al. 2013)

Increase adipocyte hypertrophy - increase hepatic fat (Muniyappa et al. 2013)

Increase in lipogenesis (Muniyappa et al. 2013)

No effect on plasma total cholesterol and triglyceride (Wargent et al. 2013)

No change in HDL cholesterol concentrations (Wargent et al. 2013)